Showing posts with label emergency medicine. Show all posts
Showing posts with label emergency medicine. Show all posts

Tuesday, 29 December 2020

Coronavirus disease 2019 (COVID-19)

Disease class: Coronavirus infections
Disease class: Respiratory tract infections
Disease class: Viral diseases

Disclaimer:

At the timing of writing, COVID-19 has been a known clinical entity for just over one year. 
This is an area of intense active research. 
The information presented herein is likely to change many times as new evidence is gathered and reported.

 

Causative pathogen

 

Pathophysiology

 

Clinical profile

 

History

 

See also

Monday, 21 December 2020

COVID19 Pathophysiology

 
This article concerns the "host side" of the infection. 
To learn more about the "viral side" (e.g. viral characteristics and virulence factors) see here: 

 

Disclaimer:

At the timing of writing, COVID-19 has been a known clinical entity for just over one year. 
This is an area of intense active research. 
The information presented herein is likely to change many times as new evidence is gathered and reported.

 

Risk factors associated with cases of severe COVID-19:

  • Advancing age
  • Tobacco smoking
  • Cancer
  • Organ dysfunction
    • Respiratory dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Cystic fibrosis 
      • Asthma (severe)
    • Heart failure
    • Chronic Kidney Disease 
    • Chronic liver disease
  • Vascular dysfunction
    • Hypertension
    • Cerebrovascular disease
  • Endocrine/Metabolic dysfunction
    • Obesity
    • Type 1 Diabetes Mellitus
    • Type 2 Diabetes Mellitus 
  • Haemoglobinopathies
    • Sickle cell disease
    • Thalassaemia
  • Pregnancy
  • Immunosuppression
    • Immunosuppressive therapy

 

There is evidence to suggest that a large spectrum of chronic diseases may increase the probability of severe disease and death.
  • Complex metabolic derangements such as obesity and Diabetes Mellitus may cause a generalised dysfunction of immunity, predisposition to inappropriately severe inflammation, or reduced physiological reserve.
  • Some pathophysiological abnormalities may interact with SARS-CoV2 directly, to cause dysfunction unique to COVID-19.
  • Chronic organ dysfunction is associated with severe disease and death. This may result from decompensation (a vulnerable organ fails to meet rising demands during an infection). There may exist a three-way dynamic interaction between increasing organ failure (failure to meet demand), an intensifying global inflammatory response, and a rising viral load.

 

Pathological findings associated with cases of severe COVID-19:

  • High blood viral load.
  • Lymphocytopoenia
    • Relatively low numbers of NK cells.
    • Relatively low numbers of T cells.
  • Monocytosis (high numbers of monocytes).
  • Hypercytokinaemia
    • High serum levels of NF-kB, CXCR2, CCL2, CCR2, TNF-alpha, IL-6.
  • Deficiencies in interferon signalling
    • Relatively low levels of Interferon-alpha
    • Relatively low expression of Interferon-Stimulated Genes.

 

The findings in severe COVID-19 appear consistent with a downward spiral of rising viral load, accumulating viral-mediated tissue damage, rising inflammatory signals, accumulating host-mediated tissue damage, depleting physiological reserves, and immune exhaustion. 


Genes with variants associated with cases of severe COVID-19:

  • DPP9
    • Enzyme
    • Healthy variant: Many potential uses. Plays a role in cell adhesion.
    • Disease variant: Potential cell surface vulnerability for viral entry.
  • IFNAR2
    • Receptor
    • Healthy variant: Component of interferon signalling pathway. Antiviral function.
    • Disease variant: Ineffective antiviral function.
  • TYK2
    • Enzyme
    • Healthy variant: Component of interferon signalling pathway. Antiviral function.
    • Disease variant: Ineffective antiviral function.
  • CCR2
    • Receptor
    • Healthy variant: Component of chemokine signalling pathway. Antiviral function.
    • Disease variant: Ineffective antiviral function.
  • OAS1
    • Enzyme. Induced by interferon signalling.
    • Healthy variant: Promotes viral mRNA degradation. Antiviral function.
    • Disease variant: Ineffective antiviral function.
 
There is evidence to suggest that specific genetic vulnerabilities in a host's antiviral defences increase the probability of severe disease and death.

 

The battle against every virus

  • The spread of a viral infection throughout a host's body can be imagined as a battle. A successful virus is achieving three primary goals:
    • It is invading new host cells at a greater rate than the rate of virus-infected cell destruction.
    • It is replicating at a greater rate than the rate of viral destruction.
    • It is spreading to new host bodies at a greater rate than the rate of host death or viral clearance.
  • A host who survives and clears a virus has achieved several goals:
    • They identified viral-infected cells, suppressed replication, and destroyed them.
    • They coordinated trafficking of immune cells to virus-infected tissues.
    • They destroyed virions at a rate faster than they could replicate or spread until no active virus remained.
    • They maintained sufficient immune function to avoid death from other infections.
    • They maintained vital physiological function (e.g. metabolism, organ function).
  • The hosts who are most likely to lose this battle are:
    • Incapable of destroying the virus at a sufficient rate.
      • Failures of a specific antiviral defence (e.g. IFNAR2) .
      • Generalised immune system dysfunction (e.g. immunosuppression).
    • Incapable of suppressing viral replication sufficiently. 
      • Failure of a specific antiviral defence (e.g. OAS1).
    • Incapable of vital physiological function while burdened with the infection.
      • Decompensated organ failure (e.g. heart failure).
      • Respiratory failure.
      • Sepsis
      • Septic shock

 

Another hypothesis

  • By causing down-regulation of ACE2 receptors throughout the body, SARS-CoV2 may interact harmfully with RAAS or the kinin–kallikrein system.
  • This may be advantageous to the virus, but it is more likely to be an unfortunate coincidence for the host.

 

Challenges in modelling COVID-19

  • Severe COVID-19 is associated with a large number of factors, which can interact with each factors in many ways.
  • This is undoubtedly a complex system. 'Complex' features include:
    • A network of interacting components (e.g. virus-cell interactions, cytokines, metabolism, organ function).
    • Feedback loops (e.g. secretion of inflammatory factors to attract cells which secrete more inflammatory factors, without resolution of the infection).
    • Emergent phenomena (e.g. the impact on the function of each organ).
    • Nonlinearity (e.g. two hosts with identical physiologies and identical risk factors may have a dramatically different course of pathophysiology on a sub-cellular, cellular, and macroscopic level)
    • Stochastic processes (e.g. intra-host virus-cell dynamics).

 

Summary

  • There is already a wealth of information available about COVID-19. Many congenital factors, and acquired factors, appear to influence the probability of severe COVID-19 and death.
  • We can expect a great deal more research over the coming years. Further research should reveal synergistic or antagonistic interactions between various combinations of factors. 
  • Advances in technology may facilitate predictive modelling.

SARS-CoV-2 VUI-202012/01

 Also known as:

  • Lineage B.1.1.7 
  • Variant Under Investigation in December 2020

 

Disclaimer:

At the timing of writing, COVID-19 has been a known clinical entity for just over one year. 
This is an area of intense active research. 
The information presented herein is likely to change many times as new evidence is gathered and reported.

 

Laconic

  • A new strain of SARS-CoV-2 with significantly greater transmissibility.

 

Disease:

 

Probable origin:

  • London, United Kingdom
  • September 2020

 

Key mutations (compared to the first SARS-CoV-2 strain)

17 in total
  • N501Y : point mutation from asparagine (N) to tyrosine (Y) in amino-acid site 501

 

Clinical consequences

  • Significantly increased affinity for ACE2 receptor binding.
  • Significantly higher viral load (on average).
  • Over 70% increase in transmissibility.
  • No obvious increase in morbidity or mortality.

 

See also:

COVID-19 pandemic

History of medicine: Pandemics


Disclaimer:

At the timing of writing, COVID-19 has been a known clinical entity for just over one year. 
This is an area of intense active research. 
The information presented herein is likely to change many times as new evidence is gathered and reported.

 

Causative agent:

 

Disease:



Timeline

  • 1st December 2019: Patient zero experiences symptoms in Wuhan.
  • Day 23: An unsolved medical case is investigated by bronchoalveolar lavage. The specimen is sent for metagenomic massive parallel sequencing analysis. 
  • Day 26: SARS-CoV2 is first identified from the specimen. 
  • Day 41: Chinese state media report the first death from COVID-19.
  • Day 49: First confirmed case outside Wuhan, in China.
  • Day 50: The Chinese state media characterises the situation as an epidemic.
  • Day 50: First confirmed cases in Singapore, Malaysia, South Korea.
  • Day 52: First confirmed case in North America (Washington state).
  • Day 52: First confirmed case in Europe (France).
  • Day 56: First confirmed case in Oceania (Australia).
  • Day 57: First confirmed case in Canada.
  • Day 60: First confirmed case in India.
  • Day 61: First confirmed case in Russia.
  • Day 62: First confirmed case in United Kingdom.
  • Day 76: First confirmed case in Africa (Egypt).
  • Day 87: First confirmed case in South America (Brazil).
  • Day 89: First confirmed case in Mexico.
  • Day 91: First confirmed case in South Africa.
  • Day 93: First confirmed case in Argentina.
  • Day 101: The World Health Organisation characterises the situation as a pandemic.
  • Day 365: Cumulative confirmed cases in the UK = 1,617,331 (2.38%)
  • Day 365: Cumulative case fatalities in the UK = 58,245 (0.10%)
  • Day 365: Cumulative confirmed cases in the world = 62,411,018 (0.79%)
  • Day 365: Cumulative case fatalities in the world = 1,458,118 (0.02%)
  • Day 386: United Kingdom announces that strain VUI-2020/01 appears significantly more transmissible than the first strain.

 

Consequences

  • Significant increase in global morbidity and mortality.
  • Significant increase in healthcare demands, leading to oversaturation, resource depletion and preventable harm to patients.
  • Millions of infections and deaths amongst healthcare workers. 
  • 2020 stock market crash
  • COVID-19 recession
  • Significant decrease in revenue for many businesses.
  • Mass closure of businesses.
  • Significant increase in unemployment.
  • Significant increase in domestic violence.
  • Significant increase in social isolation and loneliness.
  • Significant increase in prevalence and severity of depression, stress, anxiety, and other mental health disorders (e.g. schizophrenia).
  • Significant increase in social inequality and poverty.

 

Further reading

Severe acute respiratory syndrome coronavirus

Pathogen category: (+)ssRNA viruses


Also known as

  • SARS-CoV-1
  • SARS virus

 

Pathology

 

Features

Exploits

  • ACE2 (Angiotensin Converting Enzyme 2). An cell surface enzyme. The viral spike protein has evolved a Receptor Binding Domain, with high binding affinity for ACE2.
  • TMPRSS2 (Transmembrane protease, serine 2): A transmembrane enzyme. SARS-CoV1 and SARS-CoV2 have evolved to initiate cell entry when they interact with this enzyme on the cell surface.

 

Taxonomy

  • Category: Virus     
  • Realm: Riboviria
  • Kingdom: Orthornavirae
  • Phylum: Pisuviricota
  • Class: Pisoniviricetes
  • Order: Nidovirales
  • Family: Coronaviridae
  • Genus: Betacoronavirus
  • Subgenus: Sarbecovirus
  • Species: Severe acute respiratory syndrome–related coronavirus

 

See also

Saturday, 19 December 2020

COVID19 Clinical profile

Disease: Novel coronavirus disease 2019 (COVID-19)

Disclaimer:

At the timing of writing, COVID-19 has been a known clinical entity for just over one year. 
This is an area of intense active research. 
The information presented herein is likely to change many times as new evidence is gathered and reported.

 

Causative pathogen

 

Symptoms

  • Anosmia
  • Pyrexia
  • Shortness of breath
  • Cough (dry)
  • Chest pain
  • Muscle ache
  • Weakness
  • Fatigue
  • Abdominal pain
  • Nausea
  • Diarrhoea
  • Confusion

 

Clinical manifestations


Differential diagnosis includes:

 

Management

  • Isolation / Quarantine
  • Contact tracing
  • Nasopharyngeal swabbing and testing for viral RNA by PCR
  • Blood tests
  • Chest radiograph
  • Arterial Blood Gas analysis

Interventions

  • Supportive management
  • Oxygen therapy 
  • Anti-coagulation therapy
  • Anti-inflammatory therapy
    • Corticosteroid treatment may reduce mortality in the population with severe disease.
    • Intravenous infusions of tocilizumab OR sarilumab may reduce mortality in the population with severe disease.
  • Vitamin D supplementation may reduce morbidity and mortality.
  • Antibiotic therapy may help to reduce any element of opportunistic bacterial infections (e.g. viral pneumonia with secondary bacterial pneumonia).

 

Saturday, 12 December 2020

Severe acute respiratory syndrome coronavirus 2

Pathogen category: (+)ssRNA viruses

Also known as

  • SARS-CoV-2
  • 2019 novel coronavirus (2019-nCoV)

 

Disclaimer:

At the timing of writing, COVID-19 has been a known clinical entity for just over one year. 
This is an area of intense active research. 
The information presented herein is likely to change many times as new evidence is gathered and reported.

 

Pathology

 

Characteristics

  • SARS-CoV2 has been described by virologists as unusually proficient at suppressing the immune response until the infection is very advanced. There can be almost no signs of viral infection in tissues which are heavily burdened with compromised cells. As a result, asymptomatic carriers can spread the virus for days before they develop any signs or symptoms.
  • SARS-CoV2 can survive on hard surfaces for up to 72 hours.
  • Hard surfaces can be effectively cleaned with alcohol or soap solutions.

 

Features

Genome

  • The genome is contained within a single, linear, positive-sense RNA strand.
  • Size (# base pairs): 29,903.

Structural proteins

  • Nucleocaspid protein (N): Houses the viral genetic material.
  • Envelope (E): Forms the outermost viral envelope.
  • Membrane (M): Forms the outermost viral envelope.
  • Spike (S): Forms the outermost viral envelope. Binds to host cell. See 'Exploits' below.

Viral envelope 

  • The virus is surrounded by a protective lipid (fatty) bilayer.

Virulence factors

  • At least 3 identified. With futher research, more factors may be recognised. 
  • Promote viral shedding.
  • Inhibit host immune response.

Exploits

  • ACE2 (Angiotensin Converting Enzyme 2). A cell surface enzyme. The viral spike protein has evolved a Receptor Binding Domain, with high binding affinity for ACE2.
  • TMPRSS2 (Transmembrane protease, serine 2): A transmembrane enzyme. SARS-CoV1 and SARS-CoV2 have evolved to initiate cell entry when they interact with this enzyme on the cell surface.


History

 

Taxonomy

  • Category: Virus     
  • Realm: Riboviria
  • Kingdom: Orthornavirae
  • Phylum: Pisuviricota
  • Class: Pisoniviricetes
  • Order: Nidovirales
  • Family: Coronaviridae
  • Genus: Betacoronavirus
  • Subgenus: Sarbecovirus
  • Species: Severe acute respiratory syndrome–related coronavirus
  • Strain: Severe acute respiratory syndrome coronavirus 2

 

See also

Wednesday, 29 April 2020

Intratracheal intubation

Therapeutic option for: Airway management


Also known as

    • Intubation
    • Endotracheal intubation

     

    Not to be confused with:

    Noninvasive ventilation

    Therapeutic option for: Artificial respiration

    Also known as

    • NIV

     

    Not to be confused with:

    • CPAP
      • This is because CPAP does not ventilate, it merely provides continuous pressure.

    Artificial respiration

    Therapeutic option for: Airway management

    Types

    Positive-Pressure Respiration

    Therapeutic option for: Artificial respiration

    Forms

    Continuous positive airway pressure

    Type of: Positive-pressure respiration

    Also known as

    • CPAP

     

    Not to be confused with:

    • NIV
      • This is because CPAP does not ventilate, it merely provides continuous pressure.

    Friday, 17 April 2020

    Heart failure: Wet and cold, hypotensive

    Presentation of Heart failure
    Wet and cold

    Wet

    • Systemic venous congestion
    • Orthopnea
    • Paroxysmal nocturnal dyspnoea
    • Breathlessness
    • Bi-basilar rales
    • An abnormal blood pressure response to the Valsalva maneuver (left-sided)
    • Symptoms of gut congestion
    • Jugular venous distension
    • Hepatojugular reflux
    • Hepatomegaly
    • Ascites
    • Peripheral oedema (right-sided)
    • Wet mucous membranes
    • Inferior vena cava does not appear collapsed on imaging
    • Improves with diuresis

    Cold

    • Poor cardiac output
    • Inadequate peripheral perfusion
    • Cold skin

     

    Hypotensive

    • Systolic blood pressure below 90 mmHg

     

    Management

    In critical care areas

    • Arterial cannulation
    • Direct measurement of mean arterial pressure
    • Inotropic therapy
    • Vasopressor therapy
    • Mechanical circulatory support

    If blood pressure climbs above 90 mmHg

    • Follow algorithm here

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Wet and cold, normotensive

    Presentation of Heart failure

    Wet

    • Systemic venous congestion
    • Orthopnea
    • Paroxysmal nocturnal dyspnoea
    • Breathlessness
    • Bi-basilar rales
    • An abnormal blood pressure response to the Valsalva maneuver (left-sided)
    • Symptoms of gut congestion
    • Jugular venous distension
    • Hepatojugular reflux
    • Hepatomegaly
    • Ascites
    • Peripheral oedema (right-sided)
    • Wet mucous membranes
    • Inferior vena cava does not appear collapsed on imaging
    • Improves with diuresis

    Cold

    • Poor cardiac output
    • Inadequate peripheral perfusion
    • Cold skin

     

    Normotensive

    • Systolic blood pressure equal to 90 mmHg or above

     

    Management

    In critical care areas

    • Arterial cannulation
    • Direct measurement of mean arterial pressure
    • Inotropic therapy

    If blood pressure falls below 90 mmHg

    • Follow algorithm here

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Dry and cold

    Presentation of Heart failure

    Dry (5% of Acute Heart Failure patients)

    • No systemic venous congestion
    • No pulmonary oedema
    • Lower probability of peripheral oedema
    • Dry mucous membranes
    • Normal jugular venous pulse
    • Inferior vena cava appears collapsed on imaging
    • Worsens with diuresis

    Cold

    • Inadequate peripheral perfusion
    • Cold skin

     

    Pathophysiology

    • Hypoperfused
    • Hypovolaemic

     

    Management

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Dry and warm

    Presentation of Heart failure

    Dry (5% of Acute Heart Failure patients)

    • No systemic venous congestion
    • No pulmonary oedema
    • Lower probability of peripheral oedema
    • Dry mucous membranes
    • Normal jugular venous pulse
    • Inferior vena cava appears collapsed on imaging
    • Worsens with diuresis

     

    Warm

    • Adequate peripheral perfusion
    • Warm skin

     

    Pathophysiology

    • If adequately perfused, this can be considered compensated heart failure.

     

    Management

    • Adjust oral therapy

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Wet and cold

    Presentation of Heart failure

    Wet (95% of Acute Heart Failure patients)

    • Systemic venous congestion
    • Orthopnea
    • Paroxysmal nocturnal dyspnoea
    • Breathlessness
    • Bi-basilar rales
    • An abnormal blood pressure response to the Valsalva maneuver (left-sided)
    • Symptoms of gut congestion
    • Jugular venous distension
    • Hepatojugular reflux
    • Hepatomegaly
    • Ascites
    • Peripheral oedema (right-sided)
    • Wet mucous membranes
    • Inferior vena cava does not appear collapsed on imaging
    • Improves with diuresis

    Cold

    • Inadequate peripheral perfusion
    • Cold skin

     

    Blood pressure

    If systolic blood pressure falls below 90 mmHg: 

    See here

     

    If systolic blood pressure remains at 90 mmHg or above:

    See here

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Wet and warm

    Presentation of Heart failure

     

    Wet (95% of Acute Heart Failure patients)

    • Systemic venous congestion
    • Orthopnea
    • Paroxysmal nocturnal dyspnoea
    • Breathlessness
    • Bi-basilar rales
    • An abnormal blood pressure response to the Valsalva maneuver (left-sided)
    • Symptoms of gut congestion
    • Jugular venous distension
    • Hepatojugular reflux
    • Hepatomegaly
    • Ascites
    • Peripheral oedema (right-sided)
    • Wet mucous membranes
    • Inferior vena cava does not appear collapsed on imaging
    • Improves with diuresis

     

    Warm

    • Adequate peripheral perfusion
    • Warm skin

     

    Predominant feature

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Wet and warm, cardiac type

    Presentation of Heart failure

    Wet (95% of Acute Heart Failure patients)

    • Systemic venous congestion
    • Orthopnea
    • Paroxysmal nocturnal dyspnoea
    • Breathlessness
    • Bi-basilar rales
    • An abnormal blood pressure response to the Valsalva maneuver (left-sided)
    • Symptoms of gut congestion
    • Jugular venous distension
    • Hepatojugular reflux
    • Hepatomegaly
    • Ascites
    • Peripheral oedema (right-sided)
    • Wet mucous membranes
    • Inferior vena cava does not appear collapsed on imaging
    • Improves with diuresis

     

    Warm

    • Adequate peripheral perfusion
    • Warm skin

     

    Predominant cause: cardiac

    • Fluid accumulation
    • Congestion predominates

     

    Management

    • Diuretic therapy
    • Vasodilator therapy
    • Ultrafiltration (consider if diuretic resistant)

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128

    Heart failure: Wet and warm, vascular type

    Presentation of Heart failure
    Wet and warm

    Wet (95% of Acute Heart Failure patients)

    • Systemic venous congestion
    • Orthopnea
    • Paroxysmal nocturnal dyspnoea
    • Breathlessness
    • Bi-basilar rales
    • An abnormal blood pressure response to the Valsalva maneuver (left-sided)
    • Symptoms of gut congestion
    • Jugular venous distension
    • Hepatojugular reflux
    • Hepatomegaly
    • Ascites
    • Peripheral oedema (right-sided)
    • Wet mucous membranes
    • Inferior vena cava does not appear collapsed on imaging
    • Improves with diuresis

     

    Warm

    • Adequate peripheral perfusion
    • Warm skin

     

    Predominant cause: vasculature

    • Fluid redistribution
    • Hypertension predominates

     

    Management

     

    References

    1. Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer, ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
      Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128